ECG parameters in children and adolescents treated with aripiprazole and risperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 51, Issue , 2014, Pages 23-27

  Germanò, Eva ^a   Italiano, Domenico ^b   Lamberti, Marco ^a   Guerriero, Laura ^a   Privitera, Carmen ^a   D'Amico, Gessica ^a   Siracusano, Rosamaria ^a   Ingrassia, Massimo ^a   Spina, Edoardo ^b   Calabrò, Maria Pia ^a   Gagliano, Antonella ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Atypical antipsychotics; Children; QT dispersion; QT prolongation

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; CHILD; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; OPEN STUDY; PR INTERVAL; PROSPECTIVE STUDY; QRS COMPLEX; QT DISPERSION; QT INTERVAL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART RATE; MENTAL DISORDERS; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MENTAL DISORDERS; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; RETROSPECTIVE STUDIES; RISPERIDONE;

EID: 84892987994     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.10.020     Document Type: Article

References (50)

1. Bazzano A.T., Mangione-Smith R., Schonlau M., Suttorp M.J., Brook R.H. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009, 9:81-88.
2. Beach S.R., Celano C.M., Noseworthy P.A., Januzzi J.L., Huffman J.C. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013, 54:1-13.
3. Biederman J., Mick E., Spencer T., Doyle R., Joshi G., Hammerness P., et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007, 12:683-689.
4. Blair J., Scahill L., State M., Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005, 44:73-79.
5. Bogun F., Chan K.K., Harvey M., Goyal R., Castellani M., Niebauer M., et al. QT dispersion in non sustained ventricular tachycardia and coronary artery disease. Am J Cardiol 1996, 77:256-259.
6. Briles J.J., Rosenberg D.R., Brooks B.A., Roberts M.W., Diwadkar V.A. Review of the safety of second-generation antipsychotics: are they really "atypically" safe for youth and adults?. Prim Care Companion CNS Disord 2012, 14(3):2012.
7. Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs 2013, 15(3):217-233.
8. Camm A.J., Karayal O.N., Meltzer H., Kolluri S., O'Gorman C., Miceli J., et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs 2012, 26:351-365.
9. Chiu C.C., Chang W.H., Huang M.C., Chiu Y.W., Lane H.Y. Regular-dose risperidone on QTc intervals. J Clin Psychopharmacol 2005, 25:391-393.
10. Correll C.U., Penzner J.B., Parikh U.H., Mughal T., Javed T., Carbon M., et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006, 15:177-206.
11. Correll C.U., Harris J., Figen V., Kane J.M., Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol 2011, 21:365-368.
12. Correll C.U., Lops J.D., Figen V., Malhotra A.K., Kane J.M., Manu P. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 2011, 72:854-860.
13. Cuddy T.E., Halli P.S., Tate R.B. QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: the Manitoba follow-up study. Prev Cardiol 2009, 12:27-33.
14. de Castro M.J., Fraguas D., Laita P., Moreno D., Parellada M., Pascual D., et al. QTc changes after 6months of second-generation antipsychotic treatment in children and adolescents. J Child Adolesc Psychopharmacol 2008, 18:381-383.
15. Devlin A.M., Ngai Y.F., Ronsley R., Panagiotopoulos C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry 2012, 24(2):e71.
16. Drici M.D., Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 2007, 16:882-890.
17. FDA US Food and Drug Administration: meeting materials 2009, Psychopharmacologic Drugs Advisory Committee.
18. Findling R.L., Short E.J., Leskovec T., Townsend L.D., Demeter C.A., McNamara N.K., et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008, 18:347-354.
19. Findling R.L., Kauffman R.E., Sallee F.R., Carson W.H., Nyilas M., Mallikaarjun S., et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Pharmacol 2008, 28:441-446.
20. Geller B., Luby J.L., Joshi P., Wagner K.D., Emslie G., Walkup J.T., et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012, 69(5):515-528.
21. Gluais P., Bastide M., Grandmougin D., Fayad G., Adamantidis M. Risperidone reduces K+ currents in human atrial myocytes and prolongs repolarization in human myocardium. Eur J Pharmacol 2004, 497:215-222.
22. Greenaway M., Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009, 18:250-260.
23. Gulisano M., Calì P.V., Cavanna A.E., Eddy C., Rickards H., Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 2011, 32:1213-1217.
24. Haddad P.M., Anderson I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62:1649-1671.
25. Ho J., Panagiotopoulos C., McCrindle B., Grisaru S., Pringsheim T. CAMESA guideline group: management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011, 20:234-241.
26. Ho J.G., Caldwell R.L., McDougle C.J., Orsagh-Yentis D.K., Erickson C.A., Posey D.J., et al. The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2012, 22:277-283.
27. Lazarczyk M.J., Bhuiyan Z.A., Perrin N., Giannakopoulos P. Selective acquired long QT syndrome (saLQTS) upon risperidone treatment. BMC Psychiatry 2012, 5(12):220.
28. Lou S., Michler K., Johnston P., Macfarlane P.W. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004, 37:81-90. [Suppl.].
29. Maayan L., Correll C.U. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011, 21:517-535.
30. Margari L., Matera E., Craig F., Petruzzelli M.G., Calmieri V.O., Pastore A., et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 2013, 28(4):177-183.
31. Masi G., Gagliano A., Siracusano R., Berloffa S., Calarese T., Ilardo G., et al. Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol 2012, 22:120-125.
32. McNally P., McNicholas F., Oslizlok P. The QT interval and psychotropic medications in children: recommendations for clinicians. Eur Child Adolesc Psychiatry 2007, 16:33-47.
33. Migliardi G., Spina E., D'Arrigo C., Gagliano A., Germanò E., Siracusano R., et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1496-1501.
34. Nahshoni E., Spitzer S., Berant M., Shoval G., Zalsman G., Weizman A. QT interval and dispersion in very young children treated with antipsychotic drugs: a retrospective chart review. J Child Adolesc Psychopharmacol 2007, 17:187-194.
35. Nielsen J., Graff C., Kanters J., Toft E., Meyer J.M. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011, 25(6):473-90. [Jun 1].
36. Olfson M., Blanco C., Liu S.M., Wang S., Correll C.U. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012, 69:1247-56.
37. Pringsheim T., Lam D., Ching H., Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children. Drug Saf 2011, 34:651-668.
38. Pringsheim T., Panagiotopoulos C., Davidson J., Ho J. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth, The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Paediatr Child Health 2011, 16(9).
39. Priori S.G., Napolitano C., Paganini V., Cantù F., Schwartz P.J. Molecular biology of the long QT syndrome: impact on management. Pacing Clin Electrophysiol 1997, 20:2052-2057.
40. Rajabi F., Hajsheikholeslami F., Beyraghi N. Sudden cardiac death after treatment with low dose risperidone in combination with cotrimoxazole. Asian J Psychiatry 2011, 4(3):218-20.
41. Rautaharju P.M., Surawicz B., Gettes L.S., Bailey J.J., Childers R., Deal B.J., et al. American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009, 53(11):982-991.
42. Raviña T., Raviña P., Gutierrez J. Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. Int J Cardiol 2007, 116:416-420.
43. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235.
44. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006, 259:59-69.
45. Rugino T.A., Janvier Y.M. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005, 20:603-610.
46. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993, 88:782-784.
47. Stigler K.A., Diener J.T., Kohn A.E., Li L., Erickson C.A., Posey D.J., et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009, 19(265-274):2009.
48. Suzuki Y., Fukui N., Watanabe J., Ono S., Sugai T., Tsuneyama N., et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol 2012, 27:39-42.
49. Vieweg W.V. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 2003, 5:205-215.
50. Woods S.W., Tully E.M., Walsh B.C., Hawkins K.A., Callahan J.L., Cohen S.J., et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry 2007, 51:s96-s101.